Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, B-1070, Belgium
Location status: Recruiting
NCT Number: NCT07594769
The purpose of this study is to assess the bioequivalence of an alternative ODT formulation (ODT2) versus the approved ODT formulation of a CGRP receptor antagonist in healthy adult participants under fasting conditions.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 1
Brussels, Bruxelles-capitale, Région de, B-1070, Belgium
Location status: Recruiting
To evaluate the bioequivalence of ODT2 (Test) versus approved ODT (Reference) formulations administered on top of the tongue in healthy adult participants under fasting conditions.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Test Formulation
Reference Formulation
Time frame: Pre-dose to 72 hours
Time frame: Pre-dose to 72 hours
Time frame: Pre-dose to 72 hours
Time frame: From baseline up to 36 days after last dose of study intervention
Contact information is provided by the study sponsor or research team.
Pfizer
Industry
A PHASE 1, OPEN LABEL, SINGLE DOSE, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF TWO FORMULATIONS OF A CGRP RECEPTOR ANTAGONIST IN HEALTHY ADULT PARTICIPANTS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07645924
Brain Diseases, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05125302
Brain Diseases, Central Nervous System Diseases
Huntsville, Alabama, United States
View Trial DetailsNCT06972056
Brain Diseases, Central Nervous System Diseases
Flagstaff, Arizona, United States
View Trial DetailsNCT07720765
Alzheimer Disease, Autoimmune Diseases
Milan, Milano, Italy
View Trial Details